Atherosclerosis Drugs Market Trends and Analysis by Application, Vertical, Region, and Segment Forecast to 2029

 Ideal for market intelligence professionals and business strategists, this research uncovers where growth is headed in the atherosclerosis drugs industry.


What Is The Current Outlook For The Atherosclerosis Drugs Market?
The atherosclerosis drugs market size has grown steadily in recent years. It will grow from $49.89 billion in 2024 to $50.91 billion in 2025 at a compound annual growth rate (CAGR) of 2.0%. The growth in the historic period can be attributed to cholesterol management, blood pressure control, smoking cessation programs, research and development, diagnostic advancements

The atherosclerosis drugs market size is expected to see steady growth in the next few years. It will grow to $58.36 billion in 2029 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to emerging therapies, precision medicine, immunotherapy and inflammation, innovations in lipid management, regulatory support. Major trends in the forecast period include biologic therapies, gene editing and gene therapy, combination therapies, personalized treatment approaches, telemedicine and remote monitoring.

Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12621&type=smp

What Are The Driving Factors Impacting The Atherosclerosis Drugs Market?
The prevalence of cardiovascular diseases is expected to propel the growth of the atherosclerosis drug market going forward. Cardiovascular diseases refer to all the diseases that can affect the heart and blood vessels, and atherosclerosis refers to the buildup of fats, cholesterol, and other substances on the artery walls of a person. Atherosclerosis is a condition characterized by the buildup of plaque inside the arteries that causes cardiovascular diseases such as coronary heart disease and stroke. Atherosclerosis drugs are used to treat cardiovascular diseases by reducing the risk of complications and managing underlying conditions such as increased cholesterol levels and blood clot formation. For instance, in September 2024, according to the data published by the Minnesota Department of Health, a US-based state health agency, approximately 30% of adults in Minnesota reported having high blood pressure in 2023, totaling nearly 1.4 million people, and in 2022, hypertensive diseases were the underlying or contributing cause of death for 14,225 residents, representing almost 28% of all deaths in the state. Therefore, the prevalence of cardiovascular diseases will drive the atherosclerosis drug market.

Analysis Of Major Segments Driving The Atherosclerosis Drugs Market Growth
The atherosclerosis drugs market covered in this report is segmented –

1) By Drug Class: Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medication, Beta Blockers, Calcium Channel Blockers, Other Drug Classes
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:
1) By Anti-Platelet Medications: Aspirin, Clopidogrel, Ticagrelor
2) By Fibric Acid And Omega-3 Fatty Acid Derivatives: Fenofibrate, Gemfibrozil, Omega-3 Fatty Acid Supplements
3) By Angiotensin-Covering Enzyme (ACE) Inhibitors: Lisinopril, Enalapril, Ramipril
4) By Diuretics: Thiazide Diuretics, Loop Diuretics, Potassium-Sparing Diuretics
5) By Cholesterol Lowering Medication: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants
6) By Beta Blockers: Metoprolol, Atenolol, Carvedilol
7) By Calcium Channel Blockers: Amlodipine, Diltiazem, Verapamil
8) By Other Drug Classes: Anticoagulants, Vasodilators, Cholesterol Absorption Inhibitors

Key Trends Driving Growth In The Atherosclerosis Drugs Market
Product innovation is a key trend gaining popularity in the atherosclerosis drugs market going forward. Major companies operating in the atherosclerosis drugs market are developing innovative drugs and getting approvals to sustain their position in the market. For instance, in March 2024, Novo Nordisk A/S, a Denmark-based healthcare company, announced the approval of Wegovy (semaglutide) for cardiovascular risk reduction in people with overweight or obesity. This is the first weight loss medication approved to reduce the risk of major cardiovascular events in adults with obesity or overweight and established cardiovascular disease, offering a new therapeutic option for this high-risk population. This dual functionality not only addresses obesity management but also plays a crucial role in preventing serious cardiovascular complications, potentially improving patient outcomes and prolonging lives.

Which Are The Top Players Involved In Atherosclerosis Drugs Market?
Major companies operating in the atherosclerosis drugs market include Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co.Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc., Anthera Pharmaceuticals Inc.

View the full atherosclerosis drugs market report here:
https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

Which Region Drives The Most Demand In The Atherosclerosis Drugs Market?
North America was the largest region in the atherosclerosis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

#Contact Us:#

The Business Research Company

Market Research Reports

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


#Follow Us On:#

LinkedIn: The Business Research Company | LinkedIn

Comments

Popular posts from this blog

Ammonia Market Forecast 2025 – Industry Trends, Challenges & Strategic Intelligence

Poultry Disinfectant Market Outlook 2025 – Global Demand, Trends & Forecast

Ammonium Sulfate Market Outlook 2025–2034 – Forecast, Trends & Growth Strategies